{"id":756,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"pt-141-bremelanotide-free-base-acetate-finished-drug-boundary","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/","title":{"rendered":"PT-141\/Bremelanotide\u00a0: fronti\u00e8re entre base libre, ac\u00e9tate et m\u00e9dicament fini"},"content":{"rendered":"
PT-141 est le code de d\u00e9veloppement associ\u00e9 au bremelanotide. Un peptide \u00e0 base libre, sa forme ac\u00e9tate et l\u2019injection finie approuv\u00e9e sont des enregistrements li\u00e9s, mais ne sont pas des mat\u00e9riaux interchangeables.<\/p>
Les preuves en un coup d'\u0153il<\/h2>
PubChem r\u00e9pertorie la base libre du bremelanotide comme un peptide cyclique \u00e0 sept r\u00e9sidus avec un poids mol\u00e9culaire 1025.2 g\/mol.<\/li>
DailyMed r\u00e9pertorie l'ac\u00e9tate de bremelanotide comme ingr\u00e9dient d\u00e9livrant 1.75 mg de bremelanotide dans 0.3 mL du produit fini approuv\u00e9.<\/li>
L'approbation r\u00e9glementaire s'applique \u00e0 la formulation, au fabricant et \u00e0 l'\u00e9tiquetage nomm\u00e9s, et non \u00e0 tous les mat\u00e9riaux utilisant PT-141 comme synonyme.<\/li><\/ul><\/div><\/div>Illustration analytique \u00e9ditoriale originale. Il ne d\u00e9crit pas un produit fourni, un lot lib\u00e9r\u00e9, une formulation approuv\u00e9e, un r\u00e9sultat de test ou une utilisation clinique.<\/figcaption><\/figure>
Fiche d'identit\u00e9<\/h2>
L'enregistrement peptidique PubChem comprend une s\u00e9quence cyclique N-ac\u00e9tyl\u00e9e avec un r\u00e9sidu D-ph\u00e9nylalanine. L'ordre des s\u00e9quences, la cyclisation et la st\u00e9r\u00e9ochimie contribuent tous \u00e0 l'identit\u00e9\u00a0; un nom marketing court ne les capture pas.<\/p>
Code de recherche<\/strong>PT-141<\/span><\/div>
Fragment actif<\/strong>Br\u00e9m\u00e9lanotide\u00a0; PubChem CID 9941379<\/span><\/div>
Ingr\u00e9dient du m\u00e9dicament fini<\/strong>Ac\u00e9tate de br\u00e9m\u00e9lanotide<\/span><\/div>
Contr\u00f4les d'identit\u00e9<\/strong>S\u00e9quence cyclique, st\u00e9r\u00e9ochimie, contre-ion, masse, chromatographie, contenu et liaison de lots<\/span><\/div><\/div><\/div>
Limite analytique et de preuve<\/h2>
La teneur en ac\u00e9tate modifie les calculs de poids de formule et de teneur. Un certificat doit indiquer si le r\u00e9sultat est rapport\u00e9 sur une base libre, sur ac\u00e9tate ou tel quel.<\/p>
N\u2019empruntez jamais l\u2019indication ou le profil de s\u00e9curit\u00e9 de Vyleesi comme preuve qu\u2019un lot du catalogue est th\u00e9rapeutiquement \u00e9quivalent. Le lien appropri\u00e9 est un lien entre les donn\u00e9es probantes et le contexte, avec une fronti\u00e8re bien visible entre le m\u00e9dicament fini.<\/p>
R\u00e8gle \u00e9ditoriale<\/h2>
Indiquez le mat\u00e9riau exact, la forme, le mod\u00e8le ou la population et le point final pris en charge par l'enregistrement cit\u00e9. Ne convertissez pas la plausibilit\u00e9 m\u00e9caniste, un r\u00e9sultat animal, une \u00e9tiquette de m\u00e9dicament fini ou un test analytique en une all\u00e9gation concernant un lot du catalogue sans rapport.<\/p>","protected":false},"excerpt":{"rendered":"
PT-141 est le code de d\u00e9veloppement associ\u00e9 au bremelanotide. Un peptide \u00e0 base libre, sa forme ac\u00e9tate et l\u2019injection finie approuv\u00e9e sont des enregistrements li\u00e9s, mais ne sont pas des mat\u00e9riaux interchangeables.<\/p>","protected":false},"author":1,"featured_media":740,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"358","pim_article_type":"Evidence and material-quality guide","pim_evidence_level":"FDA label plus curated chemical and peptide identity records","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"RECONNECT bremelanotide phase 3 trials\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31599840\/\",\"note\":\"Primary phase 3 publication; PMID 31599840.\"},{\"title\":\"DailyMed Vyleesi prescribing information\",\"url\":\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf\",\"note\":\"Current FDA-approved finished-drug label.\"},{\"title\":\"PubChem Bremelanotide record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bremelanotide\",\"note\":\"Free-base peptide identity; CID 9941379.\"}]","footnotes":""},"categories":[20],"tags":[],"class_list":["post-756","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-quality-guides"],"yoast_head":"\n
PT-141\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary<\/title>\n<meta name=\"description\" content=\"PT-141 is the development code associated with bremelanotide. A free-base peptide, its acetate form and the approved finished injection are related records\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PT-141\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary\" \/>\n<meta property=\"og:description\" content=\"PT-141 is the development code associated with bremelanotide. A free-base peptide, its acetate form and the approved finished injection are related records\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"PT-141\\\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/\"},\"wordCount\":263,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-identity-boundary.webp\",\"articleSection\":[\"Evidence & Quality Guides\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/\",\"name\":\"PT-141\\\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-identity-boundary.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"PT-141 is the development code associated with bremelanotide. A free-base peptide, its acetate form and the approved finished injection are related records\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-identity-boundary.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-identity-boundary.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Analytical distinction among PT-141 free base, acetate and finished formulation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PT-141\\\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PT-141\/Bremelanotide\u00a0: fronti\u00e8re entre base libre, ac\u00e9tate et m\u00e9dicament fini","description":"PT-141 est le code de d\u00e9veloppement associ\u00e9 au bremelanotide. Un peptide \u00e0 base libre, sa forme ac\u00e9tate et l\u2019injection finie approuv\u00e9e sont des enregistrements li\u00e9s\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/","og_locale":"fr_FR","og_type":"article","og_title":"PT-141\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary","og_description":"PT-141 is the development code associated with bremelanotide. A free-base peptide, its acetate form and the approved finished injection are related records\u2026","og_url":"https:\/\/nhdbio.com\/fr\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"PT-141\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/"},"wordCount":263,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp","articleSection":["Evidence & Quality Guides"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/","url":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/","name":"PT-141\/Bremelanotide\u00a0: fronti\u00e8re entre base libre, ac\u00e9tate et m\u00e9dicament fini","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"PT-141 est le code de d\u00e9veloppement associ\u00e9 au bremelanotide. Un peptide \u00e0 base libre, sa forme ac\u00e9tate et l\u2019injection finie approuv\u00e9e sont des enregistrements li\u00e9s\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp","width":1672,"height":941,"caption":"AI-generated illustration: Analytical distinction among PT-141 free base, acetate and finished formulation"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/pt-141-bremelanotide-free-base-acetate-finished-drug-boundary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"PT-141\/Bremelanotide: Free Base, Acetate and Finished-Drug Boundary"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=756"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/756\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/740"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Distinction](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-identity-boundary.webp\")